Get the Stockscreener App
40.85
0.15%
0.06
After Hours:
40.85
Alkermes Plc stock is traded at $40.85, with a volume of 2.29M.
It is up +0.15% in the last 24 hours and down -16.99% over the past month.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
See More
Previous Close:
$40.79
Open:
$40.94
24h Volume:
2.29M
Relative Volume:
1.21
Market Cap:
$6.85B
Revenue:
$1.56B
Net Income/Loss:
$152.72M
P/E Ratio:
45.42
EPS:
0.8994
Net Cash Flow:
$221.80M
1W Performance:
-5.85%
1M Performance:
-16.99%
6M Performance:
+39.09%
1Y Performance:
+50.57%
1-Day Range:
$40.49
$41.12
1-Week Range:
$40.49
$44.79
52-Week Range:
$27.00
$55.67
Alkermes Plc Stock (ALKS) Company Profile
Name
Alkermes Plc
Sector
Phone
00-353-1-772-8000
Address
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS vs TAK, TEVA, HLN, ZTS, VTRS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
40.85 | 6.85B | 1.56B | 152.72M | 221.80M | 0.8994 |
TAK
Takeda Pharmaceutical Co Adr
|
18.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.19 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.26 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
71.05 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
VTRS
Viatris Inc
|
17.83 | 20.48B | 14.57B | -296.50M | 1.64B | -0.259 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-29-26 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Nov-11-25 | Initiated | Truist | Buy |
| Sep-26-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-03-25 | Initiated | Wells Fargo | Overweight |
| Jul-15-25 | Initiated | Goldman | Buy |
| Jun-17-25 | Upgrade | UBS | Neutral → Buy |
| May-28-25 | Initiated | Needham | Buy |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-04-25 | Upgrade | UBS | Sell → Neutral |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Nov-05-24 | Upgrade | Stifel | Hold → Buy |
| Jun-17-24 | Initiated | TD Cowen | Buy |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-20-24 | Downgrade | UBS | Neutral → Sell |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Oct-24-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-17-23 | Initiated | UBS | Neutral |
| Nov-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-14-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-16-22 | Initiated | Piper Sandler | Neutral |
| Apr-22-22 | Resumed | Goldman | Buy |
| Apr-20-22 | Initiated | Goldman | Buy |
| Jan-27-22 | Upgrade | Cantor Fitzgerald | Hold → Overweight |
| Dec-01-21 | Initiated | Citigroup | Neutral |
| Oct-07-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-02-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-20 | Upgrade | Mizuho | Neutral → Buy |
| Jul-30-20 | Downgrade | Goldman | Neutral → Sell |
| Feb-14-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-14-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Jan-31-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-15-19 | Upgrade | Goldman | Sell → Neutral |
| May-31-19 | Initiated | H.C. Wainwright | Neutral |
| May-01-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Downgrade | Goldman | Neutral → Sell |
| Dec-14-18 | Initiated | Wolfe Research | Underperform |
| Dec-13-18 | Downgrade | Credit Suisse | Outperform → Underperform |
| Nov-05-18 | Initiated | Piper Jaffray | Neutral |
| Aug-07-18 | Initiated | Stifel | Hold |
| Jun-21-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-06-18 | Initiated | B. Riley FBR, Inc. | Buy |
| May-16-18 | Upgrade | Citigroup | Neutral → Buy |
| May-11-18 | Initiated | BofA/Merrill | Buy |
View All
Alkermes Plc Stock (ALKS) Latest News
Alkermes plc Hired Firms, 2023 - OpenSecrets
Alkermes plc Hired Firms, 2011 - OpenSecrets
Alkermes: Idiopathic Hypersomnia Could Expand LUMRYZ Into A Larger Growth, Margin Driver - Seeking Alpha
Alkermes (ALKS) Reports Early ADHD Drug Results. Can a Larger Trial Show it Works? - Insider Monkey
Alkermes Must Face Bulk Of Addiction Treatment Drug Suit - Law360
Alkermes Fails to Fend Off Addiction Treatment Antitrust Claim - Bloomberg Law News
Alkermes plc (AKD.DE) Analyst Insights, Price Targets & RecommendationsYahoo Finance - Yahoo! Finance Canada
Alkermes PLC (ALKS) Shares Fall 3.2% -- GF Value Says Still Over - GuruFocus
ALKS Reinstated by Goldman Sachs -- Rating Set to Neutral - GuruFocus
Alkermes plc (ALKS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Goldman Sachs resumes Alkermes stock coverage with neutral rating - Investing.com
ALKS Looks 29.1% Overvalued on GF Value™ - GuruFocus
Alkermes Says Experimental Drug Could Open New Path in ADHD Treatment - Yahoo
Alkermes: The Orexin Upside Is Real, But Takeda And Lilly Stand In The Way (Downgrade) - Seeking Alpha
Why Alkermes (ALKS) Is Down 6.0% After First ADHD Data For Orexin Agonist ALKS 7290 - Yahoo Finance
Annual Research Grant Program Expands Focus to Include Narcolepsy - Sleep Review
ALKS News | ALKERMES PLC (NASDAQ:ALKS) - ChartMill
ALKS Reiterated by RBC Capital -- Price Target Maintained at $56 - GuruFocus
ALKS Maintains by Baird -- Price Target Raised to $61.00 - GuruFocus
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290 - finance.yahoo.com
Alkermes reports positive top-line Phase Ib trial data for ALKS 7290 - Clinical Trials Arena
TD Cowen reiterates Alkermes stock Buy rating on ADHD trial data - Investing.com Australia
Form 8K Alkermes plc. For: 21 September By Investing.com - Investing.com Nigeria
Alkermes Shares Jump 6.5% After ADHD Drug Shows Clinical Proof-of-Concept - finance.biggo.com
ALKS Looks 34.7% Overvalued on GF Value™ - GuruFocus
Alkermes' ALKS7290 shows strong early results i... - Pluang
ALKS Reiterates by Needham -- Price Target Maintained at $62.00 - GuruFocus
Alkermes Announces Positive Phase 1 Topline Results for ALKS 7290 in ADHD Treatment - Kalkine Media
Stifel reiterates Alkermes stock rating on ADHD drug trial data By Investing.com - Investing.com Australia
Alkermes reports positive phase 1 data for ADHD drug candidate By Investing.com - Investing.com Australia
ALKS Looks 33.1% Overvalued on GF Value™ as ADHD Drug Shows Earl - GuruFocus
Alkermes rises on phase 1 results for ADHD drug ALKS 7290 - Seeking Alpha
Alkermes Shares Rise 6.5% After Positive Phase 1b Results for ADHD Drug ALKS 7290 - Yahoo Finance
Why is Alkermes stock surging today? By Investing.com - Investing.com Canada
Alkermes stock jumps on positive ADHD drug trial results - Investing.com
Alkermes reports positive phase 1 data for ADHD drug candidate - Investing.com
Alkermes Announces Positive Phase 1b Results for ALKS 7290 in Adults With ADHD - TradingView
Alkermes plc: Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) - FinanzNachrichten.de
An ADHD drug in testing cut symptom scores by 19 points - Stock Titan
Alkermes Plc (ALKS) Stock Analysis: A Look At Its 29.88% Potential Upside - DirectorsTalk Interviews
ALKS Looks 33.6% Overvalued on GF Value™ as Shares Drop to June Lows - GuruFocus
Alkermes PLC (ALKS) Shares Fall 7.1% -- What GF Score of 64 Tells Investors - GuruFocus
Alkermes Falls as Investors Appear to Take Profits Despite No Obvious Negative Company Update - Quiver Quantitative
Anne Clem Whitaker is director at Alkermes (NASDAQ: ALKS) with no reported holdings - Stock Titan
Alkermes slides 7%, reaching multi-month low (ALKS:NASDAQ) - Seeking Alpha
Alkermes Strengthens Board with New Director Appointment - The Globe and Mail
REGBlackRock GroupSAR 6ALKERMES PLC - TradingView
Form 8K Alkermes plc. For: 16 September By Investing.com - Investing.com Nigeria
Alkermes Expands Board with Anne C. Whitaker Appointment and Details Compensation Package - Kalkine Media
Alkermes Appoints Anne C. Whitaker to Board of Directors - citybiz
New Alkermes (NASDAQ: ALKS) director to get $600,000 in stock awards - Stock Titan
Alkermes Plc Stock (ALKS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.18%
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):